Whalesbook
India mein Diabetes ka Naya Oral Ilaaj Shuru!
Dr Reddy's Laboratories ab India mein Obeda naam ki oral semaglutide biosimilar la chuki hai. Ye roj khane wali tablet type 2 diabetes mellitus ke liye hai aur Dr Reddy's ke GLP-1 receptor agonists mein ek bada addition hai. India mein kiye gaye Phase III clinical trial ke baad isko approval mila hai, jismein Obeda original oral semaglutide jitni hi effective aur safe paayi gayi. Trial mein fasting plasma glucose, post-prandial plasma glucose, weight loss aur HbA1c levels mein similar improvement dikha.
Obeda 3 mg, 7 mg aur 14 mg doses mein milegi, jinke prices ₹99, ₹135 aur ₹225 hain. Is launch se Dr Reddy's ko India ke bade diabetes market mein entry mil jayegi.
India ka Badhta Diabetes Market aur Competition
India mein diabetes ek badi problem hai, jahan 101 million se zyada adults affected hain aur 11.4% prevalence rate hai. Iske alawa, 136 million log prediabetic stage mein hain. India mein GLP-1 therapies ka market bhi tezi se badal raha hai.
Novo Nordisk ka Rybelsus pehle se hi oral semaglutide mein popular hai, lekin March 2026 ke aas paas India mein patent expiry ke baad generic manufacturers se zabardast competition aa rahi hai. Torrent Pharma generic semaglutide market mein ek bada player ban gaya hai, April 2026 tak 38% share ke saath. Dr Reddy's ne bhi same period mein lagbhag 8-10% market share pakad liya hai.
Competition ke bawajood, oral semaglutide ki sales badhi hain, jo February 2026 mein ₹24 crore se badhkar April 2026 mein ₹27 crore ho gayi. Dr Reddy's apni in-house development aur manufacturing expertise ka use karke quality medication ki steady supply ensure karne ka plan bana rahi hai.
Company ka stock pichle 52 hafton mein $12.19 se $16.17 ke beech raha hai. Iska P/E ratio lagbhag 23-26 hai, jo pharmaceutical sector mein growth ki expectations dikhata hai.
Price Wars aur Margin Pressure se Challenges
Ek zaruri medical need ko address karne ke bawajood, Dr Reddy's ko India ke semaglutide market mein badi challenges face karni pad rahi hain. Kai generic competitors ke aane se, jinmein 50 se zyada brands hone ki umeed hai, prices mein tezi se kami aane ki sambhavna hai. Reports ke mutabik, generic semaglutide prices original drug se 60% se 70% kam ho sakti hain. Kuch Sun Pharma generics ₹750 per weekly injection mein bhi mil rahe hain. Dr Reddy's ne apni version ki price ₹4,200 per month rakhi hai.
Iske alawa, company ke financial results mein profit margins kam hote dikh rahe hain. Gross margins Q4 FY26 mein 44.8% ho gaye aur poore saal ke liye 52.8% rahe, jo pichhle saal ke 58.5% se kam hai. FY26 ke liye net income bhi 24.22% kam hua. Yeh difficult pricing environment aur kam hoti profitability, Obeda ke long-term financial contribution ko affect kar sakti hai, khaas kar jab market mein affordable options zyada ho jayenge.
Future Plans: Wider Access aur Global Reach
M.V. Ramana, CEO of Dr. Reddy's, ne kaha hai ki Obeda ka launch advanced diabetes treatment ko India mein zyada accessible banane ki taraf ek step hai. Company apni development process ke through reliable supply aur consistent quality provide karne ke liye committed hai.
India se bahar dekhein toh, Dr Reddy's ne haal hi mein Canada mein apni generic semaglutide injection launch ki hai, jisse wo G7 nations mein aisi GLP-1 therapy approve karne wala pehla desh ban gaya hai. Ye Dr Reddy's ki strategy ke saath align karta hai jiska aim globally affordable diabetes treatments ka access badhana hai. Company Canada, Turkey aur Brazil jaise markets mein bhi enter karne ka plan bana rahi hai.
Analysts ne Dr. Reddy's Laboratories ko abhi 'Hold' rating di hai, aur average price target current stock price se lagbhag 24.1% upside dikha raha hai.